Biopharma Deals and Funding Trends through Q1 2023 from DealForma

Biopharma Deals and Funding Trends – Review of 2022 and Updates through Q1 2023

by Chris DokomajilarApr 3, 2023Analysis, Funding, M&A, Partnership Deals

Deal Flow in 2022 Returned to pre-2019 Levels

Chart showing number of healthcare and life sciences deals by deal type

Lower Deal Dollars Across All Healthcare and Life Sciences

Licensing Terms are Shifting to More in Milestones

Large Cap Biopharma In-Licensing and Buying in 2022

Big Pharma Pays Well for Phase II as POC Returns

Large Cap Biopharma Therapy Areas and Modalities in Focus

R&D Partnership Activity in Oncology

R&D Partnership Activity in Neurology

R&D Partnership Upfronts in the Top Modalities

Healthcare and Life Sciences Venture Returned to pre-2020

All Company Stages Saw Lower Venture Activity

Biopharma M&A Volume Increased in Q1

21,598

Licensing Deals

22,217

Funding Rounds

4,216

M&A

35,278

Company Profiles

5,897

Other Deals

27,588

Drug Sales Figures

All of this by stage, disease indication, modality, target...

Schedule Your Demo

More Research by DealForma

Biopharma Venture Investment Through Q3 2023

Dec 1, 2023 | Analysis, Funding

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Nov 22, 2023 | Analysis, M&A

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Nov 17, 2023 | Analysis, Partnership Deals

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...